BioSpace News Archive

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics

Inscopix today announced a new research effort that leverages its brain mapping platform and single-cell transcriptomics for a more nuanced understanding of Parkinson’s disease (PD) and identification of novel targets for therapeutic development

Creative Medical Technology Holdings, Inc., a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, provided shareholder updates.

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May 21st, 2019, the Nomination Committee for the annual general meeting 2020 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30th,

SCYNEXIS, Inc. has received notification from the State of New Jersey of its available unused net operating losses (NOLs) and R&D tax credits that can be sold under the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program.

Detailed primary results of lebrikizumab Phase 2b study to be presented at the Fall Clinical Dermatology Conference

PHILADELPHIA, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Spark TMS , a leading mental health service provider in Philadelphia, will host their first-ever live demonstration of BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) helmet for the public. Deep TMS is a medication-free, noninvasive treatment used to treat obsessive-compulsive disorder (OCD). The “End OCD Now” demo event will take place on Wednesday, Oct. 16 from 4:30 p.m. to 7:00 p.m., which coincides with OCD Awareness Week

Values-driven investment firm, Kingdom Capital, today announced the launch of PercayAI, an augmented intelligence software company that helps researchers develop new drugs more quickly and successfully.

Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC.

Terms of the deal were not publicly disclosed.